Cowealth Medical Holding Co., Ltd. (4745) AI Stock Analysis

Cowealth Medical Holding Co., Ltd.

(TPEx:4745)

Select Model

Rating:39Underperform

Price Target:TWD 10.00▼(-2.91% Downside)

Action:initiatedcoverage

Date:11/10/26

The score is driven primarily by severe profitability and cash-flow deterioration, with additional pressure from bearish technical trends and loss-based valuation. The strong equity base, moderate leverage, and oversold technical readings provide only limited support.

Positive Factors

Manageable LeverageA debt-to-equity ratio around 0.35 indicates a comparatively moderate and stable capital structure for the business. This preserves financial flexibility to support operations and future investment, while reducing the balance-sheet strain that can amplify downturns.

Negative Factors

Revenue and Profitability DeclineThe 2025 decline in revenue alongside a swing to operating and net losses shows that recent earnings power has weakened materially. Continued pressure on demand, price mix, or cost leverage could reduce reinvestment capacity and make a return to sustainable profitability more difficult.

Cowealth Medical Holding Co., Ltd. (4745) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 698.63M
Dividend Yield: ―
Average Volume (3M): 24.97K
Price to Earnings (P/E): -3.2
Beta (1Y): 0.31
Revenue Growth: -13.59%
EPS Growth: -221.93%
Country: TW
Employees: 919
Sector: General
Sector Strength: 55
Industry: Medical - Distribution

Cowealth Medical Holding Co., Ltd. Business Overview & Revenue Model

Company Description

Cowealth Medical Holding Co., Ltd., together with its subsidiaries, engages in trading of medical equipment, reagents, and spare parts in Taiwan, China, and Hong Kong. It operates in two segments, Sells Equipment, and Sells Reagents and Others. The c...

Cowealth Medical Holding Co., Ltd. Financial Statement Overview

Summary

Financial performance is weak overall: revenue and margins declined sharply, the company reported a substantial net loss, and free cash flow nearly disappeared. A solid equity base and moderate leverage provide partial support, but the supplied financial scores average below the permitted minimum and are capped at 37.

Income Statement

15Very Negative

Balance Sheet

60Neutral

Cash Flow

20Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Jun 2024	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.90B	2.96B	4.19B	4.81B	5.63B	5.14B
Gross Profit	386.14M	353.22M	791.52M	996.45M	1.10B	1.06B
EBITDA	-256.46M	-225.35M	168.15M	359.59M	470.59M	429.04M
Net Income	-294.84M	-246.56M	629.00K	55.71M	94.11M	139.46M
Balance Sheet
Total Assets	7.19B	7.04B	6.96B	6.64B	7.21B	5.40B
Cash, Cash Equivalents and Short-Term Investments	636.46M	1.14B	1.23B	927.28M	1.43B	842.68M
Total Debt	601.44M	1.01B	872.70M	647.24M	956.20M	913.34M
Total Liabilities	2.27B	1.99B	1.76B	1.61B	2.00B	1.88B
Stockholders Equity	2.70B	2.87B	2.80B	2.72B	2.84B	2.57B
Cash Flow
Free Cash Flow	-543.21M	836.00K	316.52M	-191.47M	-293.96M	-155.04M
Operating Cash Flow	-532.04M	15.53M	373.97M	45.02M	-267.59M	-118.38M
Investing Cash Flow	76.13M	-174.03M	40.60M	-173.28M	-271.00M	-13.51M
Financing Cash Flow	-142.12M	-122.23M	-238.92M	-316.48M	1.07B	-198.56M

Cowealth Medical Holding Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4745 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4745	39Underperform	TWD 685.38M	-3.19	―	―	-13.59%	-221.93%

* General Sector Average

Performance Comparison

TW:4745 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4745	Cowealth Medical Holding Co., Ltd.	10.30	-8.45	-45.07%
TW:4117	General Biologicals Corp.	7.41	-4.79	-39.26%
TW:6817	Winston Medical Supply Co., Ltd.	37.50	-60.57	-61.76%
TW:6999	Han Biomedical, Inc.	24.45	-6.02	-19.75%
TW:7726	CARILEX MEDICAL INC.	32.15	-5.10	-13.69%
TW:7835	H2U Corporation	14.55	-25.40	-63.58%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Cowealth Medical Holding Co., Ltd. AI Stock Analysis